nice buy side build up, page-4

SHC is probably being positively influenced by LVAD companies getting some success eg HIN

SHC also shares a common director with Mesoblast. They're having positive indications with Revascor( a cell therapy) re: early results Phase 2 trials.
http://investors.cephalon.com/phoenix.zhtml?c=81709&p=irol-newsArticle&ID=1514406&highlight=

http://clinicaltrials.gov/ct2/show/NCT00721045?term=revascor&rank=1


Mesoblast (Revascor) have another trial going with LVADS.
http://clinicaltrials.gov/ct2/show/record/NCT00927784?term=revascor&rank=2

Revascor adds uncertainty to the landscape, therefore probably explains the recent softening of the share price.